Podcast Pearls: Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

Download this slideset to learn more about the clinical trials discussed in our podcast focused on PARP inhibitor combination approaches to broaden the utility of PARP inhibition in prostate cancer.
Karim Fizazi, MD, PhD
Joaquin Mateo, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 297 KB
Released: April 19, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

Related Content

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 4, 2021

Clinical Care Options (CCO) commentary of expert insights on FGFR alterations and targeted therapies for bladder and urothelial carcinoma

Andrea Necchi, MD Released: April 30, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue